Lentiviral labeling of mouse and human enteric nervous system stem cells for regenerative medicine studies. by Natarajan, D et al.
TECHNICAL NOTE
Lentiviral labeling of mouse and human enteric nervous
system stem cells for regenerative medicine studies
D. NATARAJAN,* J. COOPER,* S. CHOUDHURY,* J.-M. DELALANDE,*,† C. MCCANN,* S. J. HOWE,‡ N. THAPAR*
& A. J. BURNS*,§
*Stem Cells and Regenerative Medicine, UCL Institute of Child Health, London, UK
†Centre for Digestive Diseases, Barts & The London School of Medicine & Dentistry, Queen Mary, University of London, London,
UK
‡Molecular and Cellular Immunology, UCL Institute of Child Health, London, UK
§Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
Key Messages
• For ENS stem cells to be used in novel cell replacement therapies for enteric neuropathies such as Hirschsprung
disease then ‘proof of principle’ animal experiments need to be extended using human cells. For such studies,
robust methods of labeling transplanted human ENS stem cells need to be established.
• Our aim was to assess the ability of lentiviral vectors expressing fluorescent reporter genes to label ENS stem
cells and trace them following transplantation into mouse gut in vivo.
• Mouse and human gut-derived cells, including ENS stem cells, were transduced with a lentiviral vector
containing eGFP (green) or mCherry (red) reporter genes and analyzed in vitro and in vivo.
• In vitro, mouse and human lentivirus-transduced cells survived, maintained intense eGFP expression,
proliferated as shown by BrdU incorporation, and formed neurospheres. When transplanted into mouse gut
in vivo, transduced cells survived up to 2 months, strongly expressed eGFP and integrated into endogenous ENS
networks.
Abstract
Background Reliable methods of labeling human
enteric nervous system (ENS) stem cells for use in
novel cell replacement therapies for enteric neuropa-
thies are lacking. Here, we explore the possibility of
using lentiviral vectors expressing fluorescent reporter
genes to transduce, label, and trace mouse and human
ENS stem cells following transplantation into mouse
gut. Methods Enteric nervous system precursors,
including ENS stem cells, were isolated from enzy-
matically dissociated mouse and human gut tissues.
Lentivirus containing eGFP or mCherry fluorescent
reporter genes was added to gut cell cultures at a
multiplicity of infection of 2–5. After fluorescence
activated cell sorting for eGFP and subsequent analy-
sis with markers of proliferation and cell phenotype,
transduced mouse and human cells were transplanted
into the gut of C57BL/6 and immune deficient Rag2-/
gamma chain-/C5 mice, respectively and analyzed up
to 60 days later. Key Results Mouse and human
transduced cells survived in vitro, maintained intense
eGFP expression, proliferated as shown by BrdU
incorporation, and formed characteristic neuro-
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spheres. When transplanted into mouse gut in vivo
and analyzed up to 2 months later, transduced mouse
and human cells survived, strongly expressed eGFP
and integrated into endogenous ENS networks.
Conclusions & Inferences Lentiviral vectors express-
ing fluorescent reporter genes enable efficient, stable,
long-term labeling of ENS stem cells when trans-
planted into in vivomouse gut. This lentiviral approach
not only addresses the need for a reliable fluorescent
marker of humanENS stem cells for preclinical studies,
but also raises the possibility of using lentiviruses for
other applications, such as gene therapy.
Keywords cell replacement therapy, enteric nervous
system stem cells, enteric neuropathies, Hirschsprung
disease, human gut, lentiviral labeling.
INTRODUCTION
Stem cell transplantation therapies for congenital
defects and degenerative diseases are rapidly becoming
a reality. A number of groups, including ours, are
focusing on establishing stem cell therapies for enteric
neuropathies such as Hirschsprung disease (HSCR),
which is characterized by an absence of the enteric
nervous system (ENS) in the distal bowel.1–3 The
ultimate aim is to transplant ENS stem cells into
defective gut to replace missing enteric neurons and
restore gut function.4–6 Supporting this idea, studies
have shown that neural crest-derived cells, the precur-
sors of the ENS,7 can be harvested from embryonic and
postnatal gut, expanded in culture to form ‘neuro-
spheres’ that contain ENS stem cells, and transplanted
into aganglionic gut, where they differentiate into
enteric neurons, and in some studies, affect gut
activity8–11 (and reviewed in Refs. 4,5,12,13). Much of
this work has been carried out in mouse models of
disease, both as source and recipient of ENS stem cell-
containing neurospheres. Genetic manipulation lead-
ing to expression of fluorescent proteins14 has been the
labeling method of choice for visualizing cells prior to
and following transplantation in vivo.11 Although such
mouse genetic approaches are powerful and effective,
their use is restricted to transgenic animals and is not
applicable for human cells. If ENS stem cells are to be
used as a therapy in HSCR patients these ‘proof of
principle’ animal experiments need to be extended
using ENS stem cells obtained from humans. For such
studies to occur, robust methods of labeling human
ENS stem cells need to be established. Here, we
demonstrate that lentiviral vectors can be used to
introduce fluorescent reporter genes into mouse and
human ENS stem cells in order to label and trace them
prior to and following transplantation into in vivo
mouse gut.
MATERIALS AND METHODS
We used a self-inactivating (SIN) second generation HIV-1 based
lentiviral vector containing the spleen focus forming virus LTR
promoter, and the mutated Woodchuck Posttranscriptional Reg-
ulatory Element, which, when placed downstream of the comple-
mentary DNA to be expressed (eGFP or mCherry reporter genes)
causes a posttranscriptional increase in transgene expression
independent of transgene, promoter or vector sequences15
(Fig. 1A).
For lentiviral vector production, a previously published
protocol was followed16,17 whereby 80% confluent 293T cells
were transfected for 4 h with 40 lg of plasmids encoding the
viral backbone (pHR’SIN), 10 lg of VSV-G envelope glycopro-
tein (pMDG.2) and 30 lg of packaging proteins (gag-pol, rev, tat,
in pCMVDR8.74) using 1 lm polyethyleneimine as a transfec-
tion agent. Cells were washed and refreshed with Dulbecco’s
Modified Eagle Medium - DMEM containing glutamine, 10%
Fetal Calf Serum - FCS and antibiotic mix and viral particles
harvested after 36 h, filtered and stored frozen unconcentrated
as 200 lL aliquots. They were titered by flow cytometry.
To isolate mouse ENS precursor cells, including ENS stem
cells, gut tissues were harvested from C57BL/6 mice aged
postnatal day 4–6, and the outer muscle layers, containing the
ENS plexus layers, were peeled and enzymatically dissociated
using a method previously described.8,10 Dissociated cells were
plated onto fibronectin-coated dishes and cultured in DMEM F12
supplemented with N2 and B27 (Life Technologies, Paisley, UK)
and Primocin antibiotics (InvivoGen, Source BioScience Life-
Sciences, Nottingham UK) and 20 ng/mL of both EGF and FGF
(both Peprotech, London, UK). Human gut tissues were either full
thickness biopsies from surgical resections or mucosal biopsies
from routine endoscopy procedures carried out on pediatric
patients. All samples were obtained with ethical approval and
informed consent at Great Ormond Street Hospital, London, UK.
Human tissue samples were dissociated and cultured using a
similar protocol to that used for mouse gut.
Dissociated cells were transduced with lentivirus carrying
either eGFP or mCherry reporter genes. Lentivirus was added to
cultures at multiplicities of infection in the range of 2–5 (100 lL
for 105 cells per well) and left for 36–48 h ensuring that the cells
attached to the dish, were transduced, and the lentivirus had
inactivated. Following trypsinization, FACS analysis was per-
formed in order to both quantify the percentage of transduced
cells, and to select eGFP+ cells which were spun down, plated on
fibronectin-coated dishes, and cultured for 7–10 days for further
analysis, including transplantation.
For BrdU labeling of cells prior to transplantation, 10 lM BrdU
(Sigma-Aldrich, Dorset, UK) was applied for 48 h followed by
fixation for immunolabeling using a previously described proto-
col.8 Antibodies used were rabbit anti-SMA (1:100; Abcam,
Cambridge, UK), mouse anti-TuJ1 (1:500; Covance, Leeds, UK),
and rat anti-BrdU (1:500, AbD Serotec, Kidlington, UK). Corre-
sponding secondary antibodies were Alexa Fluor goat anti-rabbit
568, goat anti-mouse 568, and anti-rat 568 (all 1:500; Life
Technologies, Paisley, UK).
Lentivirus-transduced mouse cells were transplanted into wild-
type C57BL/6 mice, and human transduced cells were trans-
planted into immune deficient Rag2-/gamma chain-/C5 mice. For
transplantations, the distal hindgut of 8–10 weeks old animals
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was exposed by laparotomy and cells were microinjected into the
gut wall using a beveled syringe needle. Recipient mice were
maintained for up to a further 60 days before sacrifice. Whole-
mount gut analysis was performed using immunohistochemistry
(anti-TuJ1) and confocal microscopy imaging (Zeiss LSM 710;
Zeiss, Cambridge, UK).
RESULTS
After lentiviral transduction with a fluorescent repor-
ter gene, 78  3.9% (n = 3) of mouse and 69  6.4%
(n = 5) of human cells were labeled with eGFP and
selected by gating with FACS (Fig. 1B). When trans-
duced cells were visualized by eGFP expression and
manually counted under a microscope, 88.4  13% of
mouse and 92.1  3.4% of human cells were eGFP+
(Fig. 1C and D). After FACS, eGFP+ cells were cultured
for up to 65 days for mouse cells and 35 days for
human cells. During this time transduced cells sur-
vived in culture and maintained eGFP expression and
intensity. They also formed characteristic neuro-
spheres within 1 week of culture for mouse cells
(Fig. 1E), and within 10 days to 2 weeks for human
cells (Fig. 1F).
Characterization of the cultures showed that cells
proliferated as shown by BrdU (15.3  1.3% of non-
transduced cells were BrdU+ compared to 13.3  1.0%
of transduced mouse cells, p > 0.05, indicating that
lentiviral transduction does not adversely affect prolif-
eration; Fig. 2A). Both neural crest-derived cells such
as neurons (15.01  2.5%), and non-neural crest cells
such as smooth muscle cells (64  6.3%) were trans-
duced by lentivirus in human gut cell cultures as
shown by eGFP expression and co-immunolabeling
with the neuronal marker TuJ1 (Fig. 2B) and the
smooth muscle marker SMA (Fig. 2C). 84.4  8.8%
of TuJ1+ neurons were also GFP+. Lentiviral transduc-
tion did not significantly affect cell fate as 18.9  3.4%
of cells were TuJ1+ in untransduced cultures vs
15.01  2.5% in transduced cultures (p > 0.05). Simi-
lar findings were obtained with SMA immunostaining
where 60.4  3.6% of cells were SMA+ in untrans-
duced cultures vs 64  6.3% in transduced cultures. In
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Figure 1 Lentiviral vector and transduced
mouse and human gut-derived cells. (A) Map
showing the lentiviral plasmid construct
that expresses either eGFP or mCherry
under the spleen focus forming virus (SFFV)
promoter and the mutated Woodchuck
Posttranscriptional Regulatory Element
(WPRE) which enhances transgene
expression and titer. (B) Representative
gating for FACS analysis of lentivirally
transduced (eGFP) mouse or human gut-
derived cells showing separation of
transduced vs non-transduced cells. (C and
D) Transduced cells highly express the eGFP
reporter gene for prolonged time in culture
(C, mouse ENS cells after 65 days and D,
human ENS cells after 35 days). (E and F)
Transduced cells form characteristic
neurospheres similar in appearance to
previously reported non-transduced cells.10
Scale bars = 50 lm (C and D) and 100 lm
(E and F).
© 2014 The Authors.
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Figure 2 Characteristics of lentivirus-transduced mouse and human gut-derived cells in vitro and following transplantation in vivo. (A) Transduced
(eGFP) mouse cells proliferate as shown by BrdU incorporation (red). Arrow shows double-labeled lentivirus-transduced eGFP expressing cell also
positive for BrdU. (B and C) Human cell phenotypes that were transduced by lentivirus include neural crest-derived neurons (B, arrow; Bi, arrowheads,
TuJ1 in red; Bii, eGFP in green) and non-neural crest-derived cells such as smooth muscle (C, SMA, red). DAPI (blue) labels all nuclei. (D) Mixed
cultures of mouse cells transduced with either eGFP (green) or mCherry (red) lentiviruses. After 2 weeks in culture, even though some cells were
juxtaposed (arrows), yellow cells (expressing both expressing eGFP and mCherry) were not observed, indicating that lentivirus cross infection does not
occur. (E) Transduced mouse ENS stem cell-containing neurospheres transplanted into recipient wild-type mouse gut. (F) Transduced human ENS
stem cell-containing neurospheres transplanted into recipient immune deficient mouse gut. In both cases, transduced cells were observed up to
2 months (E, mouse) and up to one month (F, human) after transplantation. High eGFP expression was maintained and transduced cells integrated
into the endogenous ENS network (TuJ1 immunolabeling, red). Transduced cells expressing TuJ1 are indicated by arrows and shown at high
magnification in insets (also showing DAPI in blue) in both panels. (G) Untransplanted TuJ1 immunolabeled mouse gut for comparison showing
enteric ganglion. Scale bars = 50 lm; A applies to A–D and E applies to E–G.
© 2014 The Authors.
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mouse cell cultures the proportions of cells immuno-
positive for TuJ1, the glial marker S100, and for SMA in
untransduced vs transduced cultures were
30.12  1.68% vs 32.38  1.6%; 18  5.29% vs
16.63  3.1%; and 69.55  4.8% vs 66.38  1.89%,
respectively (p > 0.05 in all cases). Of the transduced
mouse cells, 90.6  10.8% of the TuJ1+ cells were
GFP+. Again, lentivirus did not preferentially trans-
duce a particular cell type (neural crest-derived or non-
neural crest-derived). This was confirmed by FACS
sorting human gut cells into p75+ve (neural crest-
derived) and p75ve (non-neural crest-derived)
populations that were equally highly transduced with
eGFP (p75+ve/eGFP 95.01  3.83%; p75ve/eGFP:
97.7  0.88% p = 0.22).
In order to verify that lentiviruses cannot
remobilize and do not spread to neighboring cells,
we transduced mouse gut-derived cells with either the
eGFP-containing lentiviral construct (green), or the
mCherry-containing construct (red). Both groups of
cells were cultured for 48 h to allow virus particles to
self-inactivate, cultured for 1 further week, then
mixed together and co-cultured for 2 weeks. After
this time, cells expressing exclusively eGFP or mCher-
ry were observed (Fig. 2D) and no double-labeled
(yellow) cells expressing both eGFP and mCherry were
evident.
In order to test the suitability of lentivirally labeled
cells for stem cell transplantation, lentivirally trans-
duced cells derived from both mouse and human gut
were transplanted (n = 10 for each) into recipient
mouse gut and analyzed up to 2 months later. Trans-
duced eGFP expressing cells were observed in trans-
planted gut by fluorescence microscopy even without
immunolabeling for eGFP, suggesting that the eGFP
intensity had not diminished in vivo. The transduced
mouse and human cells included smooth muscle cells
and enteric neurons, as evidenced by eGFP expression
and immunoreactivity for SMA and for TuJ1 (Fig. 2E
and F), and TuJ1+ cells showed integration into the
endogenous ENS networks (Fig. 2E and F).
DISCUSSION
Here, we report the use of lentiviruses to fluorescently
label mouse and human gut-derived cells for gut
transplantation studies. Some previous studies have
employed retroviral or adenoviral vectors to label and
track enteric or CNS-derived neural stem cells trans-
planted into gut.8,18,19 However, lentiviruses have
advantages over these previous approaches by infecting
both dividing and non-dividing cells, providing long-
term, stable transgene expression, low immunogenic-
ity, and adequate payload capacity for the majority of
cDNAs and most marker genes, making them very
useful for transducing a range of cell types.20–22
Specifically, we found the transduction efficiency of
lentivirus to be high (~90%) compared with that
reported for adenovirus transduction of mouse neural
stem cells (up to 25% in 72 h19). In our study,
lentivirus maintained efficient, stable, long-term label-
ing of gut-derived cells, including ENS stem cells.
Transduced cells survived, proliferated and expressed
fluorescent reporter genes for an extended period of
time in vitro and in vivo. They also formed neuro-
spheres that were similar in appearance to neuro-
spheres derived from non-transduced cells as
previously reported.10 Our findings therefore highlight
the use of lentiviruses for cell tracing and lineage
analysis following transplantation of transduced
human cells into mouse gut.
This lentiviral method for labeling human cells can
also be utilized prior to, or following, selection of cells
with a NCC-specific antibody such as p75NTR to obtain
enriched populations of neural crest-derived cells.23
This combined methodology, generating eGFP+/p75+
cells, may enhance the ability of selected cells to
rescue the ENS compared to a non-enriched, mixed cell
population derived from dissociated gut. Further excit-
ing applications of lentivirally transduced ENS stem
cells include the possibility of delivering genes to
target genetically defective human ENS stem cells
(e.g., those from patients with mutations in RET or
EDNRB3,24) as a somatic gene therapy tool for restora-
tion of cell function.18,19,25
Despite the fact that further research is required in
order to understand and refine the use of lentiviruses in
cell or gene therapy, the labeling method described
here is likely to become an essential part of the toolkit
for preclinical transplantation studies of human ENS
stem cells.
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